Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MAPK3 (mitogen-activated protein kinase 3)

Written2010-01Seda Tuncay, Sreeparna Banerjee
Department of Biological Sciences, Middle East Technical University, Ankara 06531, Turkey

(Note : for Links provided by Atlas : click)

Identity

Alias_namesPRKM3
Alias_symbol (synonym)ERK1
p44mapk
p44erk1
Other aliasEC 2.7.11.24
ERK-1
ERT2
HS44KDAP
HUMKER1A
MAPK 1
MGC20180
P44ERK1
P44MAPK
p44-ERK1
p44-MAPK
HGNC (Hugo) MAPK3
LocusID (NCBI) 5595
Atlas_Id 425
Location 16p11.2  [Link to chromosome band 16p11]
Location_base_pair Starts at 30128158 and ends at 30134630 bp from pter ( according to hg19-Feb_2009)  [Mapping MAPK3.png]
Local_order According to NCBI Map Viewer, genes flanking ERK1 (MAPK3) in centromere to telomere direction on 16p11.2 are:
centromere
- Hypothetical LOC100271831, Location: 16p11.2
- YPEL3, yippee-like 3 (Drosophila), Location: 16p11.2
- GDPD3, glycerophosphodiester phosphodiesterase domain containing 3, Location: 16p11.2
- MAPK3, 16p11.2
- CORO1A, coronin, actin binding protein 1A, Location: 16p11.2
- BOLA2B, bolA homolog 2B (E. coli), Location: 16p11.2
- GIYD1, GIY-YIG domain containing 1, Location: 16p11.2
telomere
Fusion genes
(updated 2016)
DOC2A (16p11.2) / MAPK3 (16p11.2)

DNA/RNA

 
  Diagram of the ERK1 (MAPK3) gene (isoform 1). Exons are represented by open boxes (in scale). Exons 1 to 8 are from the 5' to 3' direction.
Description According to Entrez Gene MAPK3 gene maps to NC_000016.9 and spans a region of 9.21 kb. According to Spidey mRNA-to-genomic alignment program ERK1 (MAPK3) variant 1 (the most common variant) has 8 exons, the sizes being 170, 183, 190, 117, 115, 132, 110, 123 bps (mRNA coordinates).
Transcription The promoter analysis of the human MAPK3 has shown that the elements responsible for basal transcriptional activity are located within 200 bp upstream of the initiation codon in the 5' UTR and rich in G/C content (80.5%). The sequence has four SP1 sites and an E box as the most relevant motifs. Site-directed mutagenesis, EMSA, and DNase I footprinting experiments proved that all these elements are required to achieve a significant level of transcription. It has also been reported that the promoter activity is strongly repressed when the cells are grown under growth arrest conditions, such as confluence or serum withdrawal.
Pseudogene No pseudogenes have been reported for MAPK3.

Protein

Note ERK1 (MAPK3) is identified by the specific TEY (Thr-Glu-Tyr) sequence in its activation loop. ERK1 (MAPK3) is activated by dual phosphorylation of tyrosine (Tyr204) and threonine (Thr202) residues which is required for complete activation of the protein. Activated ERK1 (MAPK3) migrates into the nucleus and phosphorylates transcription factors.
Description ERK1 (MAPK3) is a 43 kDa protein consisting of 379 amino acids. ERK1 (MAPK3) protein is 85% identical to ERK2 (MAPK1) (another MAP kinase family member) and the two proteins have even higher levels of similarity in their substrate binding regions. ERK1 (MAPK3) and ERK2 (MAPK1) both possess 2 DXXD docking sites that provide interaction sites with a Kinase Interaction Motif (KIM), which can be found on activators (MAPKK), inhibitors (PTP-SL (PTPRR) and dual specificity phosphatases) and substrates (ELK-1).
Expression Ubiquitously expressed with varying levels in different tissues.
Localisation Subcellular location of ERK1 (MAPK3) protein is the cytoplasm, and the nucleus. Upon activation by dual phosphorylation on its Tyr and Thr residues by upstream kinases, ERK1 (MAPK3) is translocated into the nucleus from cytoplasm where it phosphorylates its nuclear targets.
Function Being one of the most studied cytoplasmic signaling pathways, the ERK pathway is activated via GTP-loading of RAS at the plasma membrane and sequential activation of a series of protein kinases. Activated RAS recruits the RAF family of kinases such as RAF1 to the plasma membrane which in turn acts as a MAPKKK and activates MAP kinase/ERK kinase 1 and 2 (MEK1 (MAP2K1) and MEK2 (MAP2K2)) by serine phosphorylation. MEK1/2 catalyze the phosphorylation of ERK1 (MAPK3) and ERK2 (MAPK1). Activated ERK1/2 (MAPK3/1) phosphorylates many different substrates involved in various cellular responses from cytoskeletal changes to gene transcription. ERK1 (MAPK3) was initially identified as an insulin-stimulated protein kinase which has an activity towards microtubule-associated protein-2. Today, it is well known that ERK1/2 (MAPK3/1) is especially involved in the control of cell proliferation, cell differentiation and cell survival.
It has been shown that activation of ERK1/2 (MAPK3/1) is crucial for cyclin D1 induction, providing a molecular link between ERK signaling and cell cycle control as cyclin D1 gene is essential for G1 to S-phase progression.
In response to Angiotensin II, ERK1/2 (MAPK3/1) regulates cell proliferation by either one of two signaling pathways which are heterotrimeric G protein/PKC zeta-dependent signaling and SRC/YES1/FYN signaling. ERK1/2 (MAPK3/1) phosphorylates specific transcription factors ELK-1 (leading to c-FOS transcriptional activity) following its translocation into the nucleus due to heterotrimeric G protein/PKC zeta-dependent signaling. Due to its phosphorylation in the cytoplasm by SRC/YES1/FYN signaling, ERK1/2 (MAPK3/1) complexes with RSK2 (RPS6KA), which in turn becomes activated and translocates into the nucleus to modulate c-FOS transcription and c-FOS protein activity.
The ERK pathway has been found to be responsible for the phosphorylation of BCL2 that contributes to cell survival, the suppression of the apoptotic effect of BAD, the up-regulation of the antiapoptotic protein MCL-1. Moreover, it has been also shown that ERK1/2 (MAPK3/1) is one of the regulators of TP53 protein accumulation and activation during the DNA damage response.
ERK1/2 (MAPK3/1) induces expression of PAI-1 (plasminogen activator type-1 inhibitor) which is closely associated with dynamic changes in cellular morphology and shape-altering physiologic processes.
ERK1/2 (MAPK3/1) has been shown to regulate PPARg1 following EGF stimulation.
CIITA is a critical transcription factor that initiates the expression of MHC class II genes and the subsequent induction of the immune response. Studies have indicated that ERK1/2 (MAPK3/1) negatively regulates CIITA by blocking expression of the CIITA gene and/or by phosphorylating CIITA at residues including serine 288, resulting in the loss of CIITA transactivation potential by enabling it to interact with CRM1 (XPO1) which causes export of CIITA protein from the nucleus.
Homology - P. troglodytes, MAPK3, mitogen-activated protein kinase 3
- C. lupus familiaris, MAPK3, mitogen-activated protein kinase 3
- B. taurus, MAPK3, mitogen-activated protein kinase 3
- M. musculus, MAPK3, mitogen-activated protein kinase 3
- R. norvegicus, MAPK3, mitogen activated protein kinase 3
- D. rerio, MAPK3, mitogen-activated protein kinase 3
- S. pombe, spk1, MAP kinase Spk1
- S. cerevisiae, FUS3, Fus3p
- K. lactis, KLLA0E10527g, hypothetical protein
- E. gossypii, AGOS_AFR019W, AFR019Wp
- M. grisea, MGG_09565, mitogen-activated protein kinase
- N. crassa, NCU02393.1, hypothetical protein ((AF348490) MAP kinase [Neurospora crassa OR74A])
- A. thaliana, ATMPK13, ATMPK13; MAP kinase/ kinase

Implicated in

Note
  
Entity Various diseases
Disease Although both ERK1 (MAPK3) and ERK2 (MAPK1) have very similar functions, ERK2-/- mice are embryonic lethal while ERK1-/- mice are viable and show normal size and fertility. Thus each isoform may have a unique role, or there may be threshold of total ERK activity for normal viability.
Although viable, ERK1-/- mice have reduced ability for thymocyte maturation and proliferation when T cell receptors are activated. These mice also show an enhancement of long term memory that was shown to be dependent on the striatum. Additionally, the loss of ERK1 results in a loss of adipocity, with the mice having fewer adipocytes than the wild type counterparts.
Oncogenesis Elevated and constitutive activation of ERK1/2 has been detected in a large number of human tumors; including colon, kidney, gastric, prostate, breast, non-small cell lung cancer, bladder, chondrosarcomas and glioblastoma multiforme which show especially high frequencies of kinase activation. The reason for constitutive activation of the ERK pathway in the majority of tumor cells seems to be due to a disorder in RAF, RAS, EGFR or other upstream signaling molecules. In addition, several studies have shown that the ERK-MAPK pathway can directly promote cell motility and the migration of tumor cells.
  
  
Entity Gastric cancer
Note Epidermal growth factor (EGF) and urokinase plasminogen activator receptor (uPAR (PLAUR)) are elevated in human gastric cancers and it has been shown that uPAR expression is induced by EGF via ERK1/2 as well as AP-1 (JUN) and NF-kB signaling pathways which in turn, stimulates cell invasiveness in human gastric cancer AGS cells.
  
  
Entity Breast cancer
Note In breast cancer patients, ERK1/2 has been found to be heavily phosphorylated on tyrosyl residues and have a 5-10 fold elevated activity compared to benign conditions (fibroadenoma and fibrocystic disease). Localization studies showed that hyperexpressed ERK1/2 mRNA localized to malignant epithelial cells. Furthermore, hyperexpression of ERK1/2 mRNA (5-20 fold) was also observed in metastatic cells within the lymph nodes of breast cancer patients. In addition, in a recent study it was also shown that phosphorylated ERK1/2 levels were significantly high in breast cancer cell lines with high metastatic potential compared to non metastatic breast cancer cell lines. beta-catenin, cyclin D1, and survivin have been shown to be downstream effectors of pERK1/2, while G1/0 proteins, phospholipase C, and protein kinase C serve as upstream activators of pERK1/2 in those cells.
  
  
Entity Colorectal cancer
Note Several lines of evidence indicate that overexpression and activation of ERK-MAPK pathway play an important part in progression of colorectal cancer. The constitutive activation of the RAF/MEK/ERK has been shown to be necessary for RAS-induced transformation of HT1080 human colon carcinoma cell line.
  
  
Entity Non-small-cell lung cancer
Note It has been found that nuclear and cytoplasmic ERK1/2 activation positively correlates with the stage and lymph node metastases in lung cancer. Therefore ERK1/2 is associated with advanced and aggressive NSCLC tumors.
  
  
Entity Bladder cancer
Note ERK1/2 has been shown to mediate TNF-alpha-induced MMP-9 expression by regulating the binding activity of the transcription factors, NF-kB, AP-1 and SP-1, in urinary bladder cancer HT1376 cells.
  
  
Entity Glioblastoma multiforme
Note The activation of ERK1/2 has been implicated in different pathobiological processes of GBM which is the most common and malignant brain tumor. The ERK1/2 activation has been linked to EGFR overexpression and hypermethylation of 9p21 locus.
  
  
Entity Prostate cancer
Note In prostate tumors, the level of activated MAP kinase were found to be increased with increasing Gleason score and tumor stage while nonneoplastic prostate tissue showed little or no staining with activated MAP kinase antiserum.
  
  
Entity Kidney cancer
Note In a high number of human renal cancers ERK1/2 has been found to be constitutively activated. Moreover, ERK1/2 activation was observed more frequently with high-grade renal cancer cells (RCC) compared to low-grade RCC.
  
  
Entity Chondrosarcomas
Note Activation of the JNK (MAPK8) and ERK signal transduction pathways have been shown to increase the activity and expression levels of their downstream effectors, transcription factors AP-1 and RUNX2. These transcription factors, in turn, stimulate genes that are involved in chondroblast cell biology, ultimately inducing chondroblastic tumorigenesis.
  
  
Entity Cardiac hypertrophy
Note It has been implicated that ERK1/2 mediate cardiac hypertrophy, which is a major risk factor for the development of arrhythmias, heart failure and sudden death.
  

Bibliography

EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
Baek MK, Kim MH, Jang HJ, Park JS, Chung IJ, Shin BA, Ahn BW, Jung YD.
Oncol Rep. 2008 Dec;20(6):1569-75.
PMID 19020743
 
The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis.
Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, Dani C, Hofman P, Pages G, Pouyssegur J, Le Marchand-Brustel Y, Binetruy B.
Diabetes. 2005 Feb;54(2):402-11.
PMID 15677498
 
Purification and properties of extracellular signal-regulated kinase 1, an insulin-stimulated microtubule-associated protein 2 kinase.
Boulton TG, Gregory JS, Cobb MH.
Biochemistry. 1991 Jan 8;30(1):278-86.
PMID 1846291
 
Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase.
Camp HS, Tafuri SR.
J Biol Chem. 1997 Apr 18;272(16):10811-6.
PMID 9099735
 
The MAPK signalling pathways and colorectal cancer.
Fang JY, Richardson BC.
Lancet Oncol. 2005 May;6(5):322-7. (REVIEW)
PMID 15863380
 
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ.
Cancer Res. 1999 Jan 15;59(2):279-84.
PMID 9927031
 
ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1.
Godeny MD, Sayeski PP.
Am J Physiol Cell Physiol. 2006 Dec;291(6):C1308-17. Epub 2006 May 24.
PMID 16723511
 
Promoter analysis of the human p44 mitogen-activated protein kinase gene (MAPK3): transcriptional repression under nonproliferating conditions.
Hernandez R, Garcia F, Encio I, De Miguel C.
Genomics. 2004 Jul;84(1):222-6.
PMID 15203221
 
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors.
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M.
Oncogene. 1999 Jan 21;18(3):813-22.
PMID 9989833
 
Crystal structure of human mono-phosphorylated ERK1 at Tyr204.
Kinoshita T, Yoshida I, Nakae S, Okita K, Gouda M, Matsubara M, Yokota K, Ishiguro H, Tada T.
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1123-7. Epub 2008 Nov 5.
PMID 18983981
 
Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.
Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J.
J Biol Chem. 1996 Aug 23;271(34):20608-16.
PMID 8702807
 
The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification.
Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J, Roldan P, Gonzalez-Darder J, Cerda-Nicolas M.
Neuropathology. 2008 Oct;28(5):507-15. Epub 2008 Apr 10.
PMID 18410277
 
Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling.
Lorenz K, Schmitt JP, Vidal M, Lohse MJ.
Int J Biochem Cell Biol. 2009 Dec;41(12):2351-5. Epub 2009 Aug 8.
PMID 19666137
 
In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms.
Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR.
Am J Pathol. 1998 Nov;153(5):1411-23.
PMID 9811332
 
Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory.
Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pages G, Valverde O, Marowsky A, Porrazzo A, Orban PC, Maldonado R, Ehrengruber MU, Cestari V, Lipp HP, Chapman PF, Pouyssegur J, Brambilla R.
Neuron. 2002 May 30;34(5):807-20.
PMID 12062026
 
Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID.
J Biol Chem. 2007 May 18;282(20):15208-16. Epub 2007 Mar 29.
PMID 17395590
 
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O.
Cancer Res. 1995 Sep 15;55(18):4182-7.
PMID 7664295
 
Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice.
Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, Auberger P, Pouyssegur J.
Science. 1999 Nov 12;286(5443):1374-7.
PMID 10558995
 
The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF.
Papachristou DJ, Papachristou GI, Papaefthimiou OA, Agnantis NJ, Basdra EK, Papavassiliou AG.
Histopathology. 2005 Dec;47(6):565-74. Erratum in: Histopathology. 2006 Feb;48(3):323.
PMID 16324193
 
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH.
Endocr Rev. 2001 Apr;22(2):153-83. (REVIEW)
PMID 11294822
 
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin.
Persons DL, Yazlovitskaya EM, Pelling JC.
J Biol Chem. 2000 Nov 17;275(46):35778-85.
PMID 10958792
 
An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development.
Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, Labrecque N, Ang SL, Meloche S.
EMBO Rep. 2003 Oct;4(10):964-8. Epub 2003 Sep 19.
PMID 14502223
 
MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type 1 gene expression upon drug-induced disruption of the microfilament and microtubule networks.
Samarakoon R, Higgins PJ.
J Cell Sci. 2002 Aug 1;115(Pt 15):3093-103.
PMID 12118065
 
The MAPK signaling cascade.
Seger R, Krebs EG.
FASEB J. 1995 Jun;9(9):726-35. (REVIEW)
PMID 7601337
 
Hyperexpression of mitogen-activated protein kinase in human breast cancer.
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC.
J Clin Invest. 1997 Apr 1;99(7):1478-83.
PMID 9119990
 
Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEP.
Tarrega C, Blanco-Aparicio C, Munoz JJ, Pulido R.
J Biol Chem. 2002 Jan 25;277(4):2629-36. Epub 2001 Nov 15.
PMID 11711538
 
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM.
Br J Cancer. 2004 Mar 8;90(5):1047-52.
PMID 14997206
 
Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator.
Voong LN, Slater AR, Kratovac S, Cressman DE.
J Biol Chem. 2008 Apr 4;283(14):9031-9. Epub 2008 Feb 1.
PMID 18245089
 

Citation

This paper should be referenced as such :
Tuncay, S ; Banerjee, S
MAPK3 (mitogen-activated protein kinase 3)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(11):1011-1015.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/MAPK3ID425ch16p11.html


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(7;9)(q34;q32) TRB/TAL2


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  Skin: Melanoma


External links

Nomenclature
HGNC (Hugo)MAPK3   6877
Cards
AtlasMAPK3ID425ch16p11
Entrez_Gene (NCBI)MAPK3  5595  mitogen-activated protein kinase 3
AliasesERK-1; ERK1; ERT2; HS44KDAP; 
HUMKER1A; P44ERK1; P44MAPK; PRKM3; p44-ERK1; p44-MAPK
GeneCards (Weizmann)MAPK3
Ensembl hg19 (Hinxton)ENSG00000102882 [Gene_View]  chr16:30128158-30134630 [Contig_View]  MAPK3 [Vega]
Ensembl hg38 (Hinxton)ENSG00000102882 [Gene_View]  chr16:30128158-30134630 [Contig_View]  MAPK3 [Vega]
ICGC DataPortalENSG00000102882
TCGA cBioPortalMAPK3
AceView (NCBI)MAPK3
Genatlas (Paris)MAPK3
WikiGenes5595
SOURCE (Princeton)MAPK3
Genetics Home Reference (NIH)MAPK3
Genomic and cartography
GoldenPath hg19 (UCSC)MAPK3  -     chr16:30128158-30134630 -  16p11.2   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)MAPK3  -     16p11.2   [Description]    (hg38-Dec_2013)
EnsemblMAPK3 - 16p11.2 [CytoView hg19]  MAPK3 - 16p11.2 [CytoView hg38]
Mapping of homologs : NCBIMAPK3 [Mapview hg19]  MAPK3 [Mapview hg38]
OMIM601795   
Gene and transcription
Genbank (Entrez)AK091009 AK307995 AY033607 AY033608 BC000205
RefSeq transcript (Entrez)NM_001040056 NM_001109891 NM_002746
RefSeq genomic (Entrez)NC_000016 NC_018927 NG_029936 NT_187260 NW_004929400
Consensus coding sequences : CCDS (NCBI)MAPK3
Cluster EST : UnigeneHs.861 [ NCBI ]
CGAP (NCI)Hs.861
Alternative Splicing GalleryENSG00000102882
Gene ExpressionMAPK3 [ NCBI-GEO ]   MAPK3 [ EBI - ARRAY_EXPRESS ]   MAPK3 [ SEEK ]   MAPK3 [ MEM ]
Gene Expression Viewer (FireBrowse)MAPK3 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)5595
GTEX Portal (Tissue expression)MAPK3
Protein : pattern, domain, 3D structure
UniProt/SwissProtP27361   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP27361  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP27361
Splice isoforms : SwissVarP27361
Catalytic activity : Enzyme2.7.11.24 [ Enzyme-Expasy ]   2.7.11.242.7.11.24 [ IntEnz-EBI ]   2.7.11.24 [ BRENDA ]   2.7.11.24 [ KEGG ]   
PhosPhoSitePlusP27361
Domaine pattern : Prosite (Expaxy)MAPK (PS01351)    PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_ST (PS00108)   
Domains : Interpro (EBI)Kinase-like_dom    MAP_kinase_CS    MAPK_ERK1/2    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser/Thr_dual-sp_kinase    Ser/Thr_kinase_AS   
Domain families : Pfam (Sanger)Pkinase (PF00069)   
Domain families : Pfam (NCBI)pfam00069   
Domain families : Smart (EMBL)S_TKc (SM00220)  
Conserved Domain (NCBI)MAPK3
DMDM Disease mutations5595
Blocks (Seattle)MAPK3
PDB (SRS)2ZOQ    4QTB   
PDB (PDBSum)2ZOQ    4QTB   
PDB (IMB)2ZOQ    4QTB   
PDB (RSDB)2ZOQ    4QTB   
Structural Biology KnowledgeBase2ZOQ    4QTB   
SCOP (Structural Classification of Proteins)2ZOQ    4QTB   
CATH (Classification of proteins structures)2ZOQ    4QTB   
SuperfamilyP27361
Human Protein AtlasENSG00000102882
Peptide AtlasP27361
HPRD03479
IPIIPI00018195   IPI00304111   IPI00983657   IPI00742900   IPI00793141   IPI01015689   IPI00975595   IPI00982739   IPI00984821   IPI00985374   IPI00982169   IPI00976191   
Protein Interaction databases
DIP (DOE-UCLA)P27361
IntAct (EBI)P27361
FunCoupENSG00000102882
BioGRIDMAPK3
STRING (EMBL)MAPK3
ZODIACMAPK3
Ontologies - Pathways
QuickGOP27361
Ontology : AmiGOMAPK cascade  MAPK cascade  activation of MAPK activity  MAPK import into nucleus  phosphotyrosine binding  positive regulation of protein phosphorylation  protein serine/threonine kinase activity  MAP kinase activity  MAP kinase activity  MAP kinase activity  protein binding  ATP binding  nucleus  nuclear envelope  nucleoplasm  nucleoplasm  mitochondrion  early endosome  late endosome  Golgi apparatus  cytosol  cytoskeleton  caveola  focal adhesion  transcription initiation from RNA polymerase I promoter  protein complex assembly  protein phosphorylation  apoptotic process  DNA damage induced protein phosphorylation  cell cycle  axon guidance  fibroblast growth factor receptor signaling pathway  response to toxic substance  regulation of phosphatidylinositol 3-kinase signaling  microtubule cytoskeleton  viral process  kinase activity  phosphorylation  peptidyl-serine phosphorylation  sensory perception of pain  arachidonic acid metabolic process  phosphatase binding  platelet activation  BMP signaling pathway  thyroid gland development  pseudopodium  positive regulation of cyclase activity  lipopolysaccharide-mediated signaling pathway  positive regulation of telomere maintenance via telomerase  regulation of stress-activated MAPK cascade  positive regulation of histone phosphorylation  positive regulation of histone acetylation  peptidyl-tyrosine autophosphorylation  Fc-epsilon receptor signaling pathway  Fc-gamma receptor signaling pathway involved in phagocytosis  outer ear morphogenesis  protein complex  response to exogenous dsRNA  positive regulation of translation  positive regulation of transcription from RNA polymerase II promoter  thymus development  regulation of sequence-specific DNA binding transcription factor activity  cartilage development  regulation of cytoskeleton organization  positive regulation of telomerase activity  Bergmann glial cell differentiation  face development  JAK-STAT cascade involved in growth hormone signaling pathway  lung morphogenesis  trachea formation  cardiac neural crest cell development involved in heart development  extracellular exosome  ERK1 and ERK2 cascade  positive regulation of ERK1 and ERK2 cascade  interleukin-1-mediated signaling pathway  response to epidermal growth factor  cellular response to mechanical stimulus  caveolin-mediated endocytosis  regulation of Golgi inheritance  scaffold protein binding  regulation of cellular response to heat  positive regulation of telomere capping  positive regulation of xenophagy  regulation of early endosome to late endosome transport  negative regulation of apolipoprotein binding  
Ontology : EGO-EBIMAPK cascade  MAPK cascade  activation of MAPK activity  MAPK import into nucleus  phosphotyrosine binding  positive regulation of protein phosphorylation  protein serine/threonine kinase activity  MAP kinase activity  MAP kinase activity  MAP kinase activity  protein binding  ATP binding  nucleus  nuclear envelope  nucleoplasm  nucleoplasm  mitochondrion  early endosome  late endosome  Golgi apparatus  cytosol  cytoskeleton  caveola  focal adhesion  transcription initiation from RNA polymerase I promoter  protein complex assembly  protein phosphorylation  apoptotic process  DNA damage induced protein phosphorylation  cell cycle  axon guidance  fibroblast growth factor receptor signaling pathway  response to toxic substance  regulation of phosphatidylinositol 3-kinase signaling  microtubule cytoskeleton  viral process  kinase activity  phosphorylation  peptidyl-serine phosphorylation  sensory perception of pain  arachidonic acid metabolic process  phosphatase binding  platelet activation  BMP signaling pathway  thyroid gland development  pseudopodium  positive regulation of cyclase activity  lipopolysaccharide-mediated signaling pathway  positive regulation of telomere maintenance via telomerase  regulation of stress-activated MAPK cascade  positive regulation of histone phosphorylation  positive regulation of histone acetylation  peptidyl-tyrosine autophosphorylation  Fc-epsilon receptor signaling pathway  Fc-gamma receptor signaling pathway involved in phagocytosis  outer ear morphogenesis  protein complex  response to exogenous dsRNA  positive regulation of translation  positive regulation of transcription from RNA polymerase II promoter  thymus development  regulation of sequence-specific DNA binding transcription factor activity  cartilage development  regulation of cytoskeleton organization  positive regulation of telomerase activity  Bergmann glial cell differentiation  face development  JAK-STAT cascade involved in growth hormone signaling pathway  lung morphogenesis  trachea formation  cardiac neural crest cell development involved in heart development  extracellular exosome  ERK1 and ERK2 cascade  positive regulation of ERK1 and ERK2 cascade  interleukin-1-mediated signaling pathway  response to epidermal growth factor  cellular response to mechanical stimulus  caveolin-mediated endocytosis  regulation of Golgi inheritance  scaffold protein binding  regulation of cellular response to heat  positive regulation of telomere capping  positive regulation of xenophagy  regulation of early endosome to late endosome transport  negative regulation of apolipoprotein binding  
Pathways : BIOCARTATPO Signaling Pathway [Genes]    Roles of -arrestin-dependent Recruitment of Src Kinases in GPCR Signaling [Genes]    Role of -arrestins in the activation and targeting of MAP kinases [Genes]    Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation [Genes]    IL 3 signaling pathway [Genes]    Keratinocyte Differentiation [Genes]    PDGF Signaling Pathway [Genes]    Bioactive Peptide Induced Signaling Pathway [Genes]    Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway [Genes]    Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases [Genes]    Phospholipids as signalling intermediaries [Genes]    fMLP induced chemokine gene expression in HMC-1 cells [Genes]    Ras Signaling Pathway [Genes]    T Cell Receptor Signaling Pathway [Genes]    CCR3 signaling in Eosinophils [Genes]    Cadmium induces DNA synthesis and proliferation in macrophages [Genes]    Integrin Signaling Pathway [Genes]    PTEN dependent cell cycle arrest and apoptosis [Genes]    IL-2 Receptor Beta Chain in T cell Activation [Genes]    CXCR4 Signaling Pathway [Genes]    EPO Signaling Pathway [Genes]    Signaling Pathway from G-Protein Families [Genes]    IGF-1 Signaling Pathway [Genes]    TGF beta signaling pathway [Genes]    Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) [Genes]    Regulation of BAD phosphorylation [Genes]    Transcription factor CREB and its extracellular signals [Genes]    Role of Erk5 in Neuronal Survival [Genes]    IL 6 signaling pathway [Genes]    Signaling of Hepatocyte Growth Factor Receptor [Genes]    Sprouty regulation of tyrosine kinase signals [Genes]    Trefoil Factors Initiate Mucosal Healing [Genes]    Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia [Genes]    BCR Signaling Pathway [Genes]    NFAT and Hypertrophy of the heart (Transcription in the broken heart) [Genes]    Ras-Independent pathway in NK cell-mediated cytotoxicity [Genes]    Pelp1 Modulation of Estrogen Receptor Activity [Genes]    Links between Pyk2 and Map Kinases [Genes]    Growth Hormone Signaling Pathway [Genes]    How Progesterone Initiates the Oocyte Maturation [Genes]    Stat3 Signaling Pathway [Genes]    Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling [Genes]    Repression of Pain Sensation by the Transcriptional Regulator DREAM [Genes]    EGF Signaling Pathway [Genes]    Fc Epsilon Receptor I Signaling in Mast Cells [Genes]    IL 2 signaling pathway [Genes]    Role of MAL in Rho-Mediated Activation of SRF [Genes]    Aspirin Blocks Signaling Pathway Involved in Platelet Activation [Genes]    Influence of Ras and Rho proteins on G1 to S Transition [Genes]    Agrin in Postsynaptic Differentiation [Genes]    Ceramide Signaling Pathway [Genes]    Regulation of eIF4e and p70 S6 Kinase [Genes]    Erk1/Erk2 Mapk Signaling pathway [Genes]    Inhibition of Cellular Proliferation by Gleevec [Genes]    Human Cytomegalovirus and Map Kinase Pathways [Genes]    Role of ERBB2 in Signal Transduction and Oncology [Genes]    Insulin Signaling Pathway [Genes]    MAPKinase Signaling Pathway [Genes]    Nerve growth factor pathway (NGF) [Genes]    Regulation of Splicing through Sam68 [Genes]   
Pathways : KEGGMAPK signaling pathway    ErbB signaling pathway    Ras signaling pathway    Rap1 signaling pathway    Chemokine signaling pathway    HIF-1 signaling pathway    FoxO signaling pathway    Oocyte meiosis    mTOR signaling pathway    PI3K-Akt signaling pathway    Adrenergic signaling in cardiomyocytes    Vascular smooth muscle contraction    Dorso-ventral axis formation    TGF-beta signaling pathway    Axon guidance    VEGF signaling pathway    Osteoclast differentiation    Focal adhesion    Adherens junction    Gap junction    Toll-like receptor signaling pathway    NOD-like receptor signaling pathway    Natural killer cell mediated cytotoxicity    T cell receptor signaling pathway    B cell receptor signaling pathway    Fc epsilon RI signaling pathway    Fc gamma R-mediated phagocytosis    TNF signaling pathway    Circadian entrainment    Long-term potentiation    Neurotrophin signaling pathway    Retrograde endocannabinoid signaling    Glutamatergic synapse    Cholinergic synapse    Serotonergic synapse    Long-term depression    Regulation of actin cytoskeleton    Insulin signaling pathway    GnRH signaling pathway    Progesterone-mediated oocyte maturation    Estrogen signaling pathway    Melanogenesis    Prolactin signaling pathway    Thyroid hormone signaling pathway    Type II diabetes mellitus    Aldosterone-regulated sodium reabsorption    Alzheimer's disease    Prion diseases    Alcoholism    Shigellosis    Salmonella infection    Pertussis    Leishmaniasis    Chagas disease (American trypanosomiasis)    Toxoplasmosis    Tuberculosis    Hepatitis C    Hepatitis B    Influenza A    Pathways in cancer    Viral carcinogenesis    Proteoglycans in cancer    Colorectal cancer    Renal cell carcinoma    Pancreatic cancer    Endometrial cancer    Glioma    Prostate cancer    Thyroid cancer    Melanoma    Bladder cancer    Chronic myeloid leukemia    Acute myeloid leukemia    Non-small cell lung cancer   
REACTOMEP27361 [protein]
REACTOME Pathways110056 [pathway]   112409 [pathway]   1169408 [pathway]   1295596 [pathway]   198753 [pathway]   202670 [pathway]   2029482 [pathway]   2559580 [pathway]   2559582 [pathway]   2559585 [pathway]   2871796 [pathway]   3371453 [pathway]   375165 [pathway]   445144 [pathway]   450341 [pathway]   456926 [pathway]   5654726 [pathway]   5654727 [pathway]   5654732 [pathway]   5654733 [pathway]   5663213 [pathway]   5673001 [pathway]   5674135 [pathway]   5674499 [pathway]   5675221 [pathway]   6802946 [pathway]   6802948 [pathway]   6802949 [pathway]   6802952 [pathway]   6802955 [pathway]   6811558 [pathway]   73728 [pathway]   74749 [pathway]   879415 [pathway]   881907 [pathway]   982772 [pathway]   
NDEx NetworkMAPK3
Atlas of Cancer Signalling NetworkMAPK3
Wikipedia pathwaysMAPK3
Orthology - Evolution
OrthoDB5595
GeneTree (enSembl)ENSG00000102882
Phylogenetic Trees/Animal Genes : TreeFamMAPK3
HOVERGENP27361
HOGENOMP27361
Homologs : HomoloGeneMAPK3
Homology/Alignments : Family Browser (UCSC)MAPK3
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMAPK3 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MAPK3
dbVarMAPK3
ClinVarMAPK3
1000_GenomesMAPK3 
Exome Variant ServerMAPK3
ExAC (Exome Aggregation Consortium)MAPK3 (select the gene name)
Genetic variants : HAPMAP5595
Genomic Variants (DGV)MAPK3 [DGVbeta]
DECIPHER (Syndromes)16:30128158-30134630  ENSG00000102882
CONAN: Copy Number AnalysisMAPK3 
Mutations
ICGC Data PortalMAPK3 
TCGA Data PortalMAPK3 
Broad Tumor PortalMAPK3
OASIS PortalMAPK3 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMAPK3  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDMAPK3
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch MAPK3
DgiDB (Drug Gene Interaction Database)MAPK3
DoCM (Curated mutations)MAPK3 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)MAPK3 (select a term)
intoGenMAPK3
NCG5 (London)MAPK3
Cancer3DMAPK3(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM601795   
Orphanet
MedgenMAPK3
Genetic Testing Registry MAPK3
NextProtP27361 [Medical]
TSGene5595
GENETestsMAPK3
Huge Navigator MAPK3 [HugePedia]
snp3D : Map Gene to Disease5595
BioCentury BCIQMAPK3
ClinGenMAPK3
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD5595
Chemical/Pharm GKB GenePA30622
Clinical trialMAPK3
Miscellaneous
canSAR (ICR)MAPK3 (select the gene name)
Probes
Litterature
PubMed499 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMAPK3
EVEXMAPK3
GoPubMedMAPK3
iHOPMAPK3
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:44:02 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.